Alaunos Therapeutics, Inc. (TCRT) director receives 8,138-share board fee grant

Rhea-AI Filing Summary

Jerman Michael Allen reported acquisition or exercise transactions in this Form 4 filing.

Alaunos Therapeutics, Inc. reported that director Michael Allen Jerman received a grant of 8,138 shares of common stock on 2026-07-23, valued at $1.92 per share. The shares were issued in lieu of board fees and increase his direct holdings to 23,759 shares.

Insider Trade Summary

Net Buyer: 8,138 shares

Net Buy 1 txn

Insider Jerman Michael Allen

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	8,138	$1.92	$16K

Holdings After Transaction: Common Stock — 23,759 shares (Direct)

Footnotes (1)

1. F1. Represents shares of common stock issued in lieu of board fees.

Key Figures

Shares granted: 8138.0000 shares Grant value per share: $1.9200 per share Shares owned after grant: 23759.0000 shares

3 metrics

Shares granted 8138.0000 shares Non-derivative common stock grant on 2026-07-23 to director Michael Allen Jerman

Grant value per share $1.9200 per share Value assigned to the 8,138-share common stock award issued in lieu of board fees

Shares owned after grant 23759.0000 shares Director’s direct holdings of Alaunos Therapeutics common stock following the reported grant

Key Terms

in lieu of board fees, Grant, award, or other acquisition, Common Stock

3 terms

in lieu of board fees financial

"Represents shares of common stock issued in lieu of board fees."

Grant, award, or other acquisition regulatory

"transaction_code_description: Grant, award, or other acquisition"

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/27/2026 - 04:16 PM Accepted by SEC EDGAR 07/27/2026 - 04:15 PM Learn about SEC filing dates

FAQ

What insider transaction did Alaunos Therapeutics (TCRT) report for Michael Allen Jerman?

Alaunos Therapeutics reported that director Michael Allen Jerman received a stock grant of 8,138 common shares on 2026-07-23 at $1.92 per share. The shares were issued in lieu of board fees, raising his direct ownership to 23,759 shares after the transaction.

How many Alaunos Therapeutics (TCRT) shares were granted to the director?

Director Michael Allen Jerman was granted 8,138 shares of Alaunos Therapeutics common stock. This non-derivative award was reported as a grant, award, or other acquisition and represents equity compensation issued instead of cash board fees for his service on the board.

At what price were the TCRT shares valued in Michael Allen Jerman’s grant?

The stock grant to Michael Allen Jerman was valued at $1.92 per share. This per-share value applies to the 8,138 shares of Alaunos Therapeutics common stock granted on 2026-07-23, as disclosed in the insider transaction details for the non-derivative award.

What are Michael Allen Jerman’s Alaunos Therapeutics (TCRT) holdings after this grant?

Following the grant, Michael Allen Jerman directly owns 23,759 shares of Alaunos Therapeutics common stock. This total reflects his position immediately after receiving the 8,138-share equity award that was issued in lieu of cash board fees for his director service.

Was the Alaunos Therapeutics (TCRT) share grant to the director part of his board compensation?

Yes. The filing specifies that the 8,138 shares granted to director Michael Allen Jerman were “issued in lieu of board fees.” This means the award represents equity compensation, substituting shares of common stock for cash fees normally paid for board service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jerman Michael Allen

(Last) (First) (Middle)

501 E LAS OLAS BLVD

SUITE 300

(Street)

FORT LAUDERDALE FLORIDA 33301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alaunos Therapeutics, Inc. [ TCRT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/23/2026		A		8,138(1)	A	$1.92	23,759	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock issued in lieu of board fees.

	Jerman Michael A	07/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)